Monoclonal antibody treatment approved in UK for coronavirus

The UK Medicines and Health Products Regulatory Agency (MHRA) has first approved the use of a treatment with monoclonal antibodies to prevent and fight the coronavirus.

After a thorough review of the evidence, the Commission for Human Medicines (CHM), the government’s independent scientific advisory body, approved the drug. Ronapréve as the first monoclonal antibody combination product.

Data from clinical trials evaluated by a team of scientists and doctors at the MHRA have shown that the drug can be used for prevent infections, treat the symptoms of an acute viral infection and reduce the likelihood of hospitalization

The drug, developed by Regeneron and Roche, is administered by injection or by tablets and acts on the lining of the respiratory system, where it binds tightly to the virus and prevents it from accessing cells, according to the MHRA.

UK Health Minister Sajid Javid highlighted the approval of the drug he considered specially designed to treat the coronavirus.

“Now we are working at the same pace as the NHS (Public Health System) and medical experts to ensure that this treatment can be implemented in patients. as soon as possible“he added.

For her part, MHRA Acting Director of Quality and Access, Samantha Atkinson, said she was satisfied that this treatment was safe and effective.

With information from Telam.

LGP